Skip to main content
TipRanks
Go Ultimate75% OFF

Compare GlaxoSmithKline (GS71) vs. Competitors

0 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
CH:GS71GlaxoSmithKlineCHF 26.12CHF 83.63B17.600.00%HoldUnlock the CH:GS71 analyst price target with TipRanks PremiumCH:GS71Unlock the CH:GS71 top-analyst price target with TipRanks Premium
GB:AZNAstraZenecaGBX 13,930.00GBX 215.52B25.903.05%Strong BuyUnlock the GB:AZN analyst price target with TipRanks PremiumCH:GS71 vs GB:AZNUnlock the GB:AZN top-analyst price target with TipRanks Premium
GB:HIKHikma PharmaceuticalsGBX 1,650.00GBX 3.40B12.203.97%Strong BuyUnlock the GB:HIK analyst price target with TipRanks PremiumCH:GS71 vs GB:HIKUnlock the GB:HIK top-analyst price target with TipRanks Premium
GB:SNSmith & NephewGBX 1,169.50GBX 9.67B20.37-8.78%HoldUnlock the GB:SN analyst price target with TipRanks PremiumCH:GS71 vs GB:SNUnlock the GB:SN top-analyst price target with TipRanks Premium
GB:BXPBeximco Pharmaceuticals Limited Sponsored GDR RegSGBX 60.00GBX 64.46B5.1646.34%―Unlock the GB:BXP analyst price target with TipRanks PremiumCH:GS71 vs GB:BXPUnlock the GB:BXP top-analyst price target with TipRanks Premium
GB:HLNHaleon PLCGBX 341.20GBX 29.78B18.81-9.76%Moderate BuyUnlock the GB:HLN analyst price target with TipRanks PremiumCH:GS71 vs GB:HLNUnlock the GB:HLN top-analyst price target with TipRanks Premium

Performance Comparison

-40%-20%0%20%40%60%80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
CH:GS71GlaxoSmithKline26.110.000.00%
GB:AZNAstraZeneca13930.00662.704.99%
GB:HIKHikma Pharmaceuticals1650.00126.088.27%
GB:SNSmith & Nephew1169.50-61.34-4.98%
GB:BXPBeximco Pharmaceuticals Limited Sponsored GDR RegS60.0021.3055.06%
GB:HLNHaleon PLC341.20-27.82-7.54%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts